Welcome to the corner office! Each month, we’ll turn to a new panel of biopharma executives for insights about leadership and management — and tips for thriving in a roller-coaster industry. To share your views in future columns, please fill out this short form. To suggest questions for our panelists, email STAT Plus Editor Liz Cooney. For this column, we asked:
How do you balance your long-term goals for your company with the short-term demands of investors?
Katrine Bosley, president and CEO, Editas Medicine, Cambridge, Mass.
Making new medicines is a long journey — biotech investors understand that. While some investors have a time horizon measured in minutes, other investors will be with a company for a decade (or longer). All investors look for evidence of progress along the way. Clearly articulating the interim accomplishments that demonstrate progress of the science and of our ability to execute is critical.
